Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 5.
FIG. 5.

GCCR ASO treatment did not result in systemic GCCR antagonism. Rats were dosed with saline (□) or GCCR ASO (▪) at a dose of 50 mg/kg twice weekly for 4 weeks. A subset of animals was challenged with dexamethasone (Dexa) 72 h after the final dose. Total mRNA was prepared from liver and analyzed for the expression of the following genes by RT-PCR (n = 4 per group). A: GCCR expression in GCCR ASO–treated rats not challenged with dexamethasone. *P < 0.05, GCCR ASO treatment vs. saline treatment. B: TAT expression after dexamethasone injection in liver and WAT. C: PEPCK expression after dexamethasone injection in liver. D: Total lymphocytes measured by counting and expressed relative to the mean percentage of lymphocytes in saline-treated rats. *P < 0.05, dexamethasone treatment vs. saline treatment.

This Article

  1. Diabetes vol. 54 no. 6 1846-1853